**AMENDMENTS TO THE CLAIMS**

This listing will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) An assay of a body fluid or tissue sample, which comprises detecting endogenic cis-hydroxyproline and endogenic derivatives thereof by quantitative analysis.

2. (previously presented) The assay of claim 1, wherein cis-4-hydroxyproline is detected.

3. (previously presented) The assay of claim 1, wherein cis-hydroxyproline and its derivatives is detected by HPLC, column chromatography, gas chromatography, mass spectroscopy, ion exchange chromatography, immunoassay, radio immunoassay, enzyme immunoassay, or fluorescence immunoassay.

4. (currently amended) A process for determining endogenic cis-hydroxyproline and its endogenic derivatives in a body fluid or tissue sample according to the assay of claim 1 which comprises eliminating disturbing substances in the body fluid or tissue sample to be analyzed and quantitatively determining cis-hydroxyproline and its derivative content in the sample.

5. (currently amended) The process of claim 4, which comprises using HPLC, gas chromatography, column chromatography, mass spectroscopy, ion exchange chromatography, RIA, ELISA or fluorescence immunoassay to quantitatively determine the endogenic cis-hydroxyproline and its endogenic derivative content in the sample.

6. (currently amended) The process of claim 4, wherein the endogenic cis-hydroxyproline and its endogenic derivative content is determined by comparing with an external standard, an internal standard, or both.

7. (currently amended) The process of claim 4, wherein the endogenic cis-4-hydroxyproline content in the body fluid and tissue sample is determined by HPLC, comprising the following steps:

a) adding an internal standard to the sample to obtain a mixture;

b) hydrolyzing the mixture to obtain a product;

c) adding at least one alkali hydroxide and at least one alkali carbonate to the product of step b);

d) adding a reagent that eliminates the disturbing substance and adding a derivatization reagent to the product of step c); and

e) determining the endogenic cis-4-hydroxyproline and its derivative content in the product of step d) by quantitative analysis.

8. (Previously presented) The process of claim 7, wherein before step b) an acid is added.

9. (Previously presented) The process of claim 8, wherein hydrolysis takes place in the presence of hydrochloric acid at a temperature ranging from 80 degrees C to 120 degrees C.

10. (Previously presented) The process of claim 7, wherein the alkali metal compounds added in step c) are hydroxides or carbonates of sodium or potassium.

11. (Previously presented) The process of claim 7, wherein the pH value in step c) is adjusted to a pH ranging from 8.5 to 9 with the addition of HCl.

12. (Previously presented) The process of claim 7, wherein in step d) ortho-phthaldialdehyde (OPA) and as the derivatization reagent an azo dye are added.

13. (currently amended) The process of claim 7, wherein prior to the quantitative analysis of endogenic cis-4-hydroxyproline and its endogenic derivatives in step e) the temperature is lowered.

14. (Previously presented) The process of claim 4, wherein the body fluid sample is a urine sample or a blood sample.

15. (Previously presented) The process of claim 7, wherein cis-3-hydroxyproline is used as the internal standard (IS).

16-19. (Cancelled)

20. (new) An assay of a body fluid or tissue sample, which comprises detecting endogenic cis-hydroxyproline and endogenic derivatives thereof by quantitative analysis in order to determine development or progression of a disease or the effect of a treatment on the progression of a disease in a body fluid or tissue sample.

21. (new) The assay of claim 20, wherein cis-4-hydroxyproline is detected.

22. (new) The assay of claim 20, wherein cis-hydroxyproline and its derivatives is detected by HPLC, column chromatography, gas chromatography, mass spectroscopy, ion exchange chromatography, immunoassay, radio immunoassay, enzyme immunoassay, or fluorescence immunoassay.

23. (new) A process for determining endogenic cis-hydroxyproline and its endogenic derivatives in a body fluid or tissue sample according to the assay of claim 1 which comprises eliminating disturbing substances in the body fluid or tissue sample to be analyzed and quantitatively determining endogenic cis-hydroxyproline and its endogenic derivative content in the sample in order to determine development or progression of a disease or the effect of a treatment on the progression of a disease in a body fluid or tissue sample.

24. (new) The process of claim 23, which comprises using HPLC, gas chromatography, column chromatography, mass spectroscopy, ion exchange chromatography, RIA, ELISA or fluorescence immunoassay to quantitatively determine the

endogenic cis-hydroxyproline and its endogenic derivative content in the sample.

25. (new) The process of claim 23, wherein the endogenic cis-hydroxyproline and its endogenic derivative content is determined by comparing with an external standard, an internal standard, or both.

26. (new) The process of claim 4, wherein the endogenic cis-4-hydroxyproline content in the body fluid and tissue sample is determined by HPLC, comprising the following steps:

a) adding an internal standard to the sample to obtain a mixture;

b) hydrolyzing the mixture to obtain a product;

c) adding at least one alkali hydroxide and at least one alkali carbonate to the product of step b);

d) adding a reagent that eliminates the disturbing substance and adding a derivatization reagent to the product of step c); and

e) determining the endogenic cis-4-hydroxyproline and its derivative content in the product of step d) by quantitative analysis in order to determine development or progression of a disease or the effect of a treatment on the progression of a disease in a body fluid or tissue sample.

27. (new) The process of claim 26, wherein before step b) an acid is added.

28. (new) The process of claim 27, wherein hydrolysis takes place in the presence of hydrochloric acid at a temperature ranging from 80 degrees C to 120 degrees C.

29. (new) The process of claim 26, wherein the alkali metal compounds added in step c) are hydroxides or carbonates of sodium or potassium.

30. (new) The process of claim 26, wherein the pH value in step c) is adjusted to a pH ranging from 8.5 to 9 with the addition of HCl.

31. (new) The process of claim 26, wherein in step d) ortho-phthaldialdehyde (OPA) and as the derivatization reagent an azo dye are added.

32. (new) The process of claim 26, wherein prior to the quantitative analysis of endogenic cis-4-hydroxyproline and its endogenic derivatives in step e) the temperature is lowered.

33. (new) The process of claim 23, wherein the body fluid sample is a urine sample or a blood sample.

34. (new) The process of claim 26, wherein cis-3-hydroxyproline is used as the internal standard (IS).